The global Postmenopausal Osteoporosis Market is estimated to be valued at US$ 4747.9 Mn or Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Postmenopausal osteoporosis refers to bone loss in women after menopause. The condition leads to decreased bone strength and increased risk of fractures. Medications such as calcium and vitamin D supplements, bisphosphonates and monoclonal antibodies are used for treatment and management of postmenopausal osteoporosis.
Market key trends:
One of the key trends in the postmenopausal osteoporosis market is the introduction of novel therapies for treatment. With the rising geriatric population susceptible to osteoporosis, drug manufacturers are investing significantly in developing new drug delivery systems, formulations and mechanisms of action to offer improved efficacy and safety. For instance, in 2021, Radius Health Inc. announced positive top-line results from the ACTIVExtend Phase 3 study evaluating TYMLOS (abaloparatide) subcutaneous injection in postmenopausal women with osteoporosis at high risk for fracture. The study met its primary endpoint, demonstrating a statistically significant reduction in the risk of new vertebral fractures for TYMLOS compared to placebo. Such novel drug approvals are expected to drive the postmenopausal osteoporosis market during the forecast period.
Market key trends:
The postmenopausal osteoporosis market has been witnessing rising trend of new drug developments and launch of pipeline drugs in the recent years. Several pharmaceutical companies are focusing on developing novel drugs such as antibody drugs, bone-building drugs etc. to treat postmenopausal osteoporosis more effectively. Moreover, increasing prevalence of osteoporosis among aging population especially postmenopausal women is further driving the market growth.
SWOT Analysis
Strength: Large patient pool suffering from postmenopausal osteoporosis presents significant growth opportunities. Weakness: High treatment cost of osteoporosis drugs limits their adoption.
Opportunity: Emerging economies with aging population present lucrative opportunities. Threats: Stiff competition from generic drug manufacturers poses pricing pressure on innovator drugs.
Key Takeaways
The global Postmenopausal Osteoporosis Market Growth is expected to witness high growth, exhibiting CAGR of 4.4% over the forecast period, due to increasing prevalence of osteoporosis among aging population. North America is expected to dominate the global market due to high awareness about osteoporosis and availability of advanced treatment options in the region. Key players operating in the postmenopausal osteoporosis are Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc. Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.